The effectiveness of a drug may be evaluated based on its potential to shrink tumours – but this doesn’t necessarily equate to improved survival rates.
National drug regulators use evidence from clinical trials to decide whether new cancer drugs will be approved for use. But these studies are often flawed.
For developing countries in Africa immunotherapy solutions is important given the high cost of cancer drugs.
Most cancer research has been done in Europe, there's minimal data on African populations.
Having cancer is bad enough, and dealing with the costs and confusion of billing systems makes things harder.
A cancer diagnosis is one of the scariest of all. The pain and fear are worsened by a confusing landscape of bills, opaque billing systems and changing insurance rules, rates and reimbursements.
Applications to list drugs on the PBS are usually submitted by the manufacturers of those drugs.
Some argue the current system of subsidising drugs in Australia needs changing to accommodate new cancer therapies. But two recent drug listings show the current system is working perfectly well.
Most common childhood cancers are leukemia and Hodgkin lymphoma.
Most children who have cancer live in the developing world where their survival rate is less than 25%. In Kenya awareness about childhood cancer is low and treatment isn't always readily available.
Some people taking these drugs can see their cancer completely disappear – there’s nothing left to see on their x-rays.
Imagine being able to offer hope to people with cancers once thought untreatable. Checkpoint immune drugs like Opdivo and Keytruda lead this new era in treatment. But they don't work for everyone.
The high cost of cancer drugs in South Africa has come under the spotlight with an investigation by the Competition Commission in the country.
Therapies on a nano scale rely on engineered nanoparticles designed to package and deliver drugs to exactly where they’re needed.
Nanoparticles are a form of transport for drugs and can go places drugs wouldn't be able to go on their own. They make drug delivery more targeted, reducing collateral damage to healthy tissues.
Weaker regulatory standards in the US can impact health everywhere.
Intuitively, it might seem desirable to speed up access to medicines. But this means more drugs will be approved that may subsequently prove unsafe or ineffective.
Despite dozens of trials internationally, the evidence on medical cannabis is unconvincing.
NSW is about to embark on the largest and most definitive clinical trial ever of medicinal cannabis for chemotherapy-induced nausea and vomiting.
The well-used drug clomipramine could target tumour cells and leave normal cells healthy – if scientists could get enough evidence for it.
Rare cancers are those where the incidence is less than six cases per 100,000 people.
Should new understandings of how cancers develop and could be targeted mean we should change the way the scheme registers cancer drugs?
The cost of cancer drugs is killing patients and it needs to stop
The US National Cancer Institute tested tens of thousands of plants and made this miraculous find.
The US National Cancer Institute screened 35,000 plants, but one particular sample collected from the bark of the Pacific Yew tree provided what is now one of the most highly prescribed cancer drugs.
The PBAC must make tough decisions about which cancer drugs to subsidise.
Most of us would agree that cancer drugs should be listed on the PBS, no matter how dear. But our health system can't afford all of them. How then are decisions about which drugs to subsidise made?
A group of oncologists have called on cancer patients to challenge the high prices charged by pharmaceutical companies for new cancer drugs.
Hope, fear, and desperation, along with the unique characteristics of the cancer drug market, create a “perfect storm” that continues to drive up prices for cancer drugs.
Doctors will be asking: am I needed here?
Plaid Cyrmu's manifesto promises greater expenditure, but at what cost?
This year marks the 50th anniversary of cisplatin’s accidental discovery as an anticancer drug.
Cancer drug cisplatin was accidentally discovered to help treat cancer in 1965. And it's been doing exactly that since it was approved for use in 1978.
Treated as an individual.
Personalised medicine is the ability to tailor therapy to an individual patient so that, as it’s often put, the right treatment is given to the right patient at the right time. But just how personal is…
Cancer cell to stem cells: the drugs are coming.
Chemotherapy is one of the most important treatments for all types of cancer. It involves the use of drugs that kill abnormally multiplying cells. The therapy uses one or more drugs in combination and…